Introduction
============

Hypertensive emergencies in children are rare and traditionally have been due to secondary underlying disease.[@b1-oaem-4-085] Due to an increase in the incidence of metabolic syndrome, the incidence of primary hypertension (HTN) has been increasing over recent years. In a 2004 study of 5102 school age children in Texas, an overall prevalence of HTN of 4.5% was reported with the strongest determinant of HTN being body mass index (BMI) ≥95th percentile.[@b2-oaem-4-085] The strong association of HTN with obesity and the marked increase in the prevalence of childhood obesity are significant health issues. The association of obesity with insulin resistance and HTN, otherwise known as metabolic syndrome, predisposes children to the development of cardiovascular disease.[@b3-oaem-4-085] These comorbidities have resulted in an increasing shift to primary HTN, as the main cause of HTN in the pediatric age range.[@b2-oaem-4-085]

The definition of HTN in the pediatric population has evolved with the development of evidence-based normative data based on age, sex, and height percentile.[@b1-oaem-4-085] Pediatric HTN is defined as systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) ≥95th percentile for sex, age, and height percentile on ≥3 separate occasions. Stage 1 HTN is defined as SBP and/or DBP measurements that range from the 95th percentile to 5 mmHg above the 99th percentile. Stage 2 HTN is defined as SBP and/or DBP measurements that are \>5 mmHg above the 99th percentile. Prehypertension is defined as SBP and/or DBP measurements that range from the 90th percentile to less than the 95th percentile.[@b4-oaem-4-085] Once confirmed on repeat measurement, stage 1 HTN is typically non-emergent and so can be evaluated over days, weeks, or even a couple of months before initiating treatment. Patients with stage 2 HTN require prompt evaluation and pharmacologic therapy. Symptomatic patients with stage 2 HTN require immediate treatment and consultation with experts in pediatric HTN.[@b4-oaem-4-085] Research has shown that only 15%--25% of hypertensive BP values are recognized by pediatric providers and recognition occurs mostly in older, taller children with recognized weight problems.[@b5-oaem-4-085],[@b6-oaem-4-085] [Table 1](#t1-oaem-4-085){ref-type="table"} demonstrates a simplified abnormal BP screening tool, based on age and sex. This simple tool was developed to identify children and adolescents who might have prehypertension or HTN and therefore need further evaluation.[@b7-oaem-4-085]

The term 'hypertensive crisis' is used to describe an acute elevation in BP that can cause rapid end-organ damage.[@b8-oaem-4-085] A hypertensive crisis may occur de novo or in those with previously diagnosed HTN.[@b1-oaem-4-085] Hypertensive crises are further separated into hypertensive urgency and hypertensive emergency.[@b8-oaem-4-085] Hypertensive urgency is defined as elevated BP without the presence of acute target-organ damage. These patients may manifest symptoms such as headache and nausea.[@b9-oaem-4-085] The distinction is not absolute and depends on clinical judgement.[@b8-oaem-4-085] A hypertensive emergency is defined by elevated BP with acute target-organ injury. Most commonly, organ injury occurs in the central nervous system, kidneys, or cardiovascular system.[@b10-oaem-4-085] Hypertensive encephalopathy may present with the insidious onset of headache, nausea, and vomiting and can progress to severe headache, confusion, visual changes, stupor, seizure, focal neurological deficits, and coma. Hypertensive encephalopathy may also result in cerebral infarction or hemorrhage, although this is more common in adults.[@b9-oaem-4-085]

Blood pressure measurement
==========================

Accurate BP measurement is critical for the evaluation of HTN and requires a few simple steps be performed. First, the BP should be measured via auscultation in the patient's right arm, with the arm at the level of the heart, ideally with the patient in seated position. This method allows direct comparison to standardized tables.[@b4-oaem-4-085],[@b7-oaem-4-085] Secondly, appropriate BP cuff location, and size is important, hence a variety of cuff sizes need to be readily available. The cuff should be placed on the mid-upper arm, at a point midway between the olecranon and the acromion with the width of the inflatable bladder being at least 40% of the arm's circumference.[@b4-oaem-4-085],[@b11-oaem-4-085] The bladder length of the cuff should cover 80%--100% of the circumference of the patient's arm.[@b12-oaem-4-085] The use of the manufacturer's lines on the cuff helps facilitate the choice of cuff for each child.[@b12-oaem-4-085] Cuffs that are too small can give falsely elevated measurements. Conversely, cuffs that are too large, can give falsely low values. Ideally, the BP should be measured after 5 minutes of rest. While this may be difficult in a busy emergency department (ED) triage room, it is important to repeat the measurement once the child is calm in the treatment room, if the triage value is outside the normal range.

Oscillometric devices are used frequently in EDs and provide a quick measurement of BP. However, these devices assess the mean arterial BP and then calculate the systolic and diastolic values.[@b13-oaem-4-085] The algorithms used for this calculation often vary by manufacturer.[@b14-oaem-4-085] Additionally, these devices need to be calibrated regularly to confirm accuracy. Oscillometric devices have their advantages and role in the ED; however, an elevated BP on one of these devices should be confirmed by manual auscultation.[@b4-oaem-4-085]

Differential diagnosis
======================

Secondary causes of HTN are more common in pediatric patients then in adults, particularly if the BP is elevated enough to cause hypertensive urgency or emergency. The differential diagnosis of pediatric hypertensive urgencies and emergencies are a function of age. In newborn infants, common etiologies include structural lesions such as renal vascular abnormalities, congenital renal and urologic anomalies, and aortic coarctation.[@b10-oaem-4-085] From infancy to 6 years, secondary causes of pediatric HTN, including acute and chronic renal parenchymal diseases, continue to be much more likely than primary causes of pediatrics HTN. Acute presentations of hypertensive crises include hemolytic uremic syndrome and acute glomerulonephritis.[@b8-oaem-4-085] Coarctation of the aorta and renal artery stenosis should also be considered in this early age group.[@b10-oaem-4-085],[@b15-oaem-4-085] Among younger school age children, primary HTN becomes more prevalent, although still remains less common than renal parenchymal and vascular causes.[@b10-oaem-4-085] After 10--12 years of age, primary HTN becomes the leading cause of pediatric HTN.[@b15-oaem-4-085] While obesity-related HTN rarely leads to acute hypertensive urgency or emergency, chronic organ failure can occur from HTN in patients with untreated obesity. Other causes of HTN can include withdrawal from chronic antihypertensive medications such as clonidine or β-adrenergic blockers, abuse of recreational drugs such as cocaine or amphetamine, medications such as oral contraceptive pills, corticosteroids, ephedrine, or pseudoephedrine, and elevated intracranial pressure.[@b15-oaem-4-085],[@b16-oaem-4-085] Severe fluid overload in patients on dialysis may also lead to severe, symptomatic HTN.[@b8-oaem-4-085] Rare endocrinologic pathology such as pheochromocytoma, hyperthyroidism and Cushing's syndrome should also be considered in the broad differential diagnosis for all age groups as well. A summary of etiologies of HTN appears in [Table 2](#t2-oaem-4-085){ref-type="table"}.

Evaluation
==========

History
-------

HTN in children is most likely to have an underlying cause, especially if severe.[@b8-oaem-4-085] Very young children, children with stage 2 HTN, and children or adolescents with clinical signs that suggest the presence of systemic conditions associated with HTN should be evaluated more extensively.[@b4-oaem-4-085]

A thorough history and physical examination are essential for the evaluation of HTN, and should be focused on assessing end-organ damage, and on determining etiology.[@b8-oaem-4-085] Severe HTN may be detected incidentally, particularly in those with long standing HTN that have acclimated and show few overt clinical symptoms. Presentations may include cardiac failure or neurologic manifestations (headache, vomiting, irritability, lethargy, altered sensorium, seizures, and facial palsy).[@b8-oaem-4-085] It is important to seek signs and symptoms suggesting renal disease (proteinuria, edema, anemia), heart disease (chest pain, exertional dyspnea, palpitations), and diseases of other organ systems (endocrinologic, rheumatologic).[@b4-oaem-4-085] In neonates, initial symptoms such as emesis and poor feeding can be nonspecific signs of HTN.[@b1-oaem-4-085]

Past medical and social history including trauma, urinary tract infections, umbilical vein catheterization, snoring, sleep problems, drug/herbals use (such as abuse of recreational drugs, oral contraceptives, and steroids) and nutritional supplement use should be investigated to tease out potential underlying etiologies.[@b4-oaem-4-085] Establishing a prior history and treatment of HTN is important as abrupt withdrawal of some hypertensive medications may cause hypertensive crises.[@b10-oaem-4-085]

Family history of HTN or endocrinopathies can also provide useful clues to the etiology of a child's HTN[@b10-oaem-4-085] and is often overlooked.[@b17-oaem-4-085]

Physical exam
-------------

A physical examination of someone with suspected HTN should include a full set of vital signs, including four-limb blood pressures.[@b10-oaem-4-085] An accurate weight and height should also be obtained. Fundoscopic exam and a full neurologic exam should be done to assess for hypertensive encephalopathy.[@b10-oaem-4-085] Fundoscopic exam may be difficult in younger children and may necessitate consultation by a pediatric ophthalmologist. The cardiovascular exam should focus on signs of ventricular hypertrophy or cardiac failure, including signs of pulmonary edema, hepatomegaly, additional heart sounds (especially S3 and S4), tachycardia, or a displaced apical impulse. The absence of femoral pulses should raise a suspicion for coarctation of the aorta. Renal artery bruits, edema, or growth failure may point to an underlying renal cause for HTN.[@b10-oaem-4-085] System specific physical exam findings may be helpful in determining the underlying etiology ([Table 3](#t3-oaem-4-085){ref-type="table"}).

Investigations
--------------

Diagnostic testing for hypertensive urgencies and emergencies in the ED should be limited to simple investigations, as the primary goal in the ED is to acutely lower the BP. Initial investigations in the ED depend on findings from the history and physical exam.[@b10-oaem-4-085] Laboratory studies should include urinalysis (specifically concentrating ability and presence of proteinuria), serum chemistries (including blood urea nitrogen, creatinine for baseline renal function, as well as for evidence of hypokalemic alkalosis found in HTN associated with renal vein stenosis[@b1-oaem-4-085]), and a compete blood count (to evaluate for evidence of microangiopathic hemolytic anemia as would be seen in hemolytic uremic syndrome and for anemia seen in chronic kidney disease). An electrocardiogram and chest X-ray should be considered to evaluate for signs of congestive heart failure or myocardial hypertrophy.[@b18-oaem-4-085] Computed tomography of the head may be warranted in the presence of abnormal neurological findings. Further testing after stabilization may include urine for catecholamines (neuroendocrine tumors), renal ultrasound with Doppler (structural abnormalities), complement C3 (acute glomerulonephritis), antinuclear antibody (lupus), echocardiography (structural abnormalities, end-organ damage, and left-ventricular hypertrophy), renin, aldosterone, and cortisol (Conn syndrome), TSH (hyperthyroidism), urine toxicology (abuse of recreational drugs including phencyclidine, cocaine metabolites, amphetamines), and urine pregnancy in postmenarcheal females (preeclampsia).[@b1-oaem-4-085],[@b10-oaem-4-085]

Management
----------

The majority of mild-to-moderate pediatric HTN seen in the ED does not require immediate intervention. These cases mandate close outpatient follow-up, evaluation, and management. Educating families prior to discharge about the consequences of incomplete follow-up is critical to reducing morbidity and mortality.

Hypertensive crises, however, necessitate immediate intervention to safely and effectively lower the BP. Current recommendations advise no more than a 25% reduction of SBP in the first 8 hours, followed by a gradual return to normal BP over 26 to 48 hours.[@b4-oaem-4-085],[@b16-oaem-4-085] A larger reduction in pressure can worsen end-organ function, lead to worsening neurological status, and possibly cause cerebrovascular compromise; and should therefore be avoided.[@b19-oaem-4-085] This is particularly true in cases of long-standing HTN where autoregulatory compensation has occurred. In these circumstances, blood flow increases as mean arterial pressure increases. The body compensates through cerebral vasoconstriction and adaptations such as arteriolar hypertrophy, shifting the autoregulatory range to a higher range than in normotensive patients.[@b9-oaem-4-085],[@b19-oaem-4-085]

Hypertensive emergencies are most commonly treated with intravenous (IV) medications. This allows for easier titration and control of the rate of decrease in BP. There have been a limited number of pediatric studies, and most treatment guidelines are based on experience. Many drugs used in the treatment of hypertensive emergencies are not approved by the US Food and Drug Administration for use in children and are used on an off-label basis.[@b16-oaem-4-085] It is important to understand the unique properties and adverse effects associated with these medications. [Table 4](#t4-oaem-4-085){ref-type="table"} highlights drugs commonly used to treat hypertensive emergencies in children. Key medications for hypertensive emergencies are discussed below.

Sodium nitroprusside
--------------------

Sodium nitroprusside is a direct arterial and venous smooth muscle vasodilator. It is one of the more commonly used agents in pediatric hypertensive emergencies due to its ease of titration to fluctuations in BP, its short half-life, and therefore rapid onset and termination of effects. It is administered as a continuous infusion. The dosage range is 0.3--0.5 µg/kg/min to a maximum of 8 µg/kg/min. Most patients respond to a rate of approximately 3 µg/kg/min.[@b10-oaem-4-085],[@b20-oaem-4-085]

Sodium nitroprusside is metabolized in erythrocytes to cyanide, then converted to thiocyanide in the liver and excreted by the kidneys. Extreme caution should be taken using this medication in children with hepatic or renal impairment. Special precautions, such as monitoring for cyanide toxicity should be used in cases where sodium nitroprusside is used for longer than 24 to 48 hours or if used in doses higher than 3 µg/kg/min.[@b10-oaem-4-085],[@b20-oaem-4-085] For prevention of cyanide toxicity, sodium thiosulfate, sodium nitrite, and amyl nitrite may be used. Amyl nitrite is currently used off-label for pediatric patients and not routinely recommended. More commonly, sodium thiosulfate is used. It is mixed with the sodium nitroprusside drip at a ratio of 10 mg sodium thiosulfate to 1 mg of sodium nitroprusside. Sodium nitrite may also be used, but caution is needed as it may lead to methhemoglobinemia.[@b19-oaem-4-085]

Hydralazine
===========

Hydralazine is a very potent arterial vasodilator that is used to reduce SBP. Its onset of action varies from 5 to 30 minutes with duration of action lasting 4 to 12 hours. Hydralazine is only available in bolus form, making it less predictable and more difficult to titrate. As a result, it has been largely replaced by more easily controlled medications. However, it has been used to control severe HTN in certain situations, particularly in neonates and pregnant teenagers. Another advantage of hydralazine is that it can be administered intramuscularly. This is especially useful when there is an immediate need to lower the BP and the patient does not have IV access.[@b16-oaem-4-085] Hydralazine may cause a lupus-like syndrome in slow acetylators,[@b4-oaem-4-085] reflex tachycardia, and salt and water retention.[@b9-oaem-4-085] Headache is also a common side effect, complicating symptomatology.

Esmolol
-------

Esmolol is a rapid onset, ultrashort-acting, cardioselective β~1~-adrenergic-blocking agent. Its rapid metabolism by an intracytoplasmic red blood cell esterase is independent of both renal and hepatic metabolism, making it well suited for critically ill children with multiorgan failure.[@b16-oaem-4-085] It is particularly useful in the management of hypertensive crisis associated with repair of congenital heart disease. Side effects are similar to those of any other beta-blocking agents including broncho-spasm, bradycardia, and congestive heart failure.[@b10-oaem-4-085]

Fenoldopam
----------

Fenoldopam is a selective dopamine~1~-receptor agonist, producing vasodilatation of the renal, coronary, cerebral, and splanchnic vasculature resulting in arterial dilatation and a lowering of the mean arterial pressure.[@b21-oaem-4-085],[@b22-oaem-4-085] Peak effects are seen within 5--15 minutes of infusion of the drug. Steady state is reached within 30 to 60 minutes of administration.[@b21-oaem-4-085] Clinical effects dissipate quickly once the infusion is stopped. The dose should be started at 0.2 µg/kg/min and may be increased every 20--30 minutes to 0.3--0.5 µg/kg/min. The maximum dose is 0.8 µg/kg/min; doses higher than this have been shown to worsen tachycardia without any additional BP benefits.[@b21-oaem-4-085],[@b22-oaem-4-085] Side effects include reflex tachycardia, increased intracranial pressure, and increased intraocular pressure.[@b10-oaem-4-085]

Labetalol
---------

Labetalol is an α- and β-sympathetic blocker that decreases peripheral vascular resistance with little or no effect on cardiac output.[@b16-oaem-4-085] It can be given as a bolus or continuous IV infusion. Effects appear within 2--5 minutes of administration; however, its long plasma half-life (3--5 hours) makes it more difficult to titrate. Labetalol is contraindicated in patients with asthma or chronic lung disease as it may precipitate bronchospasm, as well as in patients with hyperkalemia or congestive heart failure due to its negative inotropic and dromotropic effects. It may also mask symptoms of hypoglycemia and should be used cautiously in children with diabetes.[@b10-oaem-4-085]

Nicardipine
===========

Nicardipine is an IV dihydropyridine calcium channel blocker that reduces peripheral vascular resistance with limited inotropic, chronotropic, and dromotropic cardiac effects.[@b10-oaem-4-085] It can be used in patients with bronchospasm and renal and hepatic failure. Onset of action begins within 15 minutes, with a half-life of 10--15 minutes. Dosing may start at 0.5 to 1 µg/kg/min to a maximum of 3 µg/kg/min. Side effects include increased intracranial pressure due to cerebral vasodilatation and should be used with caution in patients with space occupying lesions. Other side effects include thrombophlebitis when given through a peripheral line, headache, nausea, tachycardia and hypotension.[@b10-oaem-4-085] Of note, nicardipine needs to be diluted in a large amount of volume, which may limit its use in those with volume overload.

Nifedipine
----------

Nifedipine is a short-acting calcium channel blocker. There is much controversy in using nifedipine to treat HTN in the pediatric population. Much of the controversy is based on adult literature, where sudden hypotension has led to ischemic complications such as strokes and myocardial ischemia.[@b10-oaem-4-085],[@b23-oaem-4-085],[@b24-oaem-4-085] Data in the pediatric literature is limited. Blaszak et al[@b25-oaem-4-085] conducted a chart review of 117 patients who received a total of 520 nifedipine doses. An initial dose of nifedipine less than 0.25 mg/kg was safe and effective, and no clinically significant side effects were noted. Egger et al[@b26-oaem-4-085] performed a review of 166 patients who received nifedipine for HTN (1746 doses). Several cases of profound and unpredictable changes in BP were noted. A few patients had clinically significant adverse events. These included change in neurologic status in six cases, profound hypotension in two patients, and oxygen desaturations in 16 cases. In many of these cases, patients had severe underlying disease and confounding factors that may have accounted for the events. However, due to the serious nature of the outcomes (stroke, seizures, altered level of consciousness, or severe symptomatic hypotension), clinicians should take great caution in using nifedipine for hypertensive emergencies in children.

Conclusion
==========

Hypertensive crises are rare in children, but must be recognized and treated promptly. Goals of ED evaluation and management are to (1) safely lower BP, and (2) treat/minimize acute end-organ damage while (3) identifying underlying etiology. IV antihypertensives are the treatment modality of choice for hypertensive emergencies with the goal of reducing SBP 25% of the original value over an 8-hour period.
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###### 

Simple table to identify children and adolescents needing further evaluation of blood pressure

  Age (years)   Males   Females         
  ------------- ------- --------- ----- ----
  3             100     59        100   61
  4             102     62        101   64
  5             104     65        103   66
  6             105     68        104   68
  7             106     70        106   69
  8             107     71        108   71
  9             109     72        110   72
  10            111     73        112   73
  11            113     74        114   74
  12            115     74        116   75
  13            117     75        117   76
  14            120     75        119   77
  15            120     76        120   78
  16            120     78        120   78
  17            120     80        120   78
  ≥18           120     80        120   80

**Notes:** These values represent the lower limits for abnormal blood pressure by age and sex. Any blood pressure readings at or higher than these values represent blood pressures in the prehypertension, stage 1 hypertension, or stage 2 hypertension range and therefore should be further evaluated by a physician.

Copyright © 2009, American Academy of Pediatrics.

Adapted with permission from Kaelber DC, Pickett F. Simple table to identify children and adolescents needing further evaluation of blood pressure. *Pediatrics.* 2009;123:e972--e974.[@b7-oaem-4-085]

**Abbreviations:** DBP, diastolic blood pressure; SBP, systolic blood pressure.

###### 

Etiology of hypertensive urgency and emergency

  Age            Etiology                                          History                                    Physical examination
  -------------- ------------------------------------------------- ------------------------------------------ -------------------------------------------------------------------------------------
  0--1 year      • Renal artery and venous thrombosis              • Umbilical artery catherization           • Pulse quality and blood pressure in four extremities
                 • Autosomal recessive polycystic kidney disease   • Oligohydramnios                          
                                                                   • Prolonged mechanical ventilation         • Signs of congestive heart failure
                 • Aortic coarctation                              • Family history of renal disease          • Abdominal mass and bruit
                 • Congenital nephritic syndrome                   • Medications                              • Ambiguous genitalia
                 • Other renal parenchymal disease                                                            
                 • Renal artery stenosis                                                                      
                 • Tumor                                                                                      
                 • Iatrogenic                                                                                 
                 • Mydriatics                                                                                 
                 • Theophylline overdose                                                                      
                 • Caffeine overdose                                                                          
  1--12 years    • Renal parenchymal disease                       • Poor feeding                             • Heart rate, body mass index, pulse quality and blood pressure in four extremities
                 • Polycystic kidney disease                       • Failure to gain weight                   
                 • Renovascular disease                            • History of urinary tract infection       • Cardiovascular/pulmonary examination
                 • Tumor                                           • History of low birth weight              
                 • Endocrine causes                                • Family history of renal disease          • Abdominal mass and bruit
                 • Aortic coarctation                              • Headache, palpitations, blurred vision   • Rash
                                                                   • Medications                              • Peripheral edema
                                                                   • Accidental ingestion                     • Retinal examination
                                                                                                              • Ambiguous genitalia
  13--18 years   • Essential hypertension                          • Excessive weight gain                    • Heart rate, body mass index, pulse quality and blood pressure in four extremities
                 • Metabolic syndrome                              • History of fever and/or joint pain       
                 • Renal parenchymal disease                       • History of urinary tract infection       • Cardiovascular/pulmonary examination
                 • Iatrogenic                                      • History of low birth weight              • Thyroid examination
                 • Anabolic steroids                               • Family history of hypertension           • Abdominal mass and bruit
                 • Substance abuse                                 or renal disease                           • Rash
                 • Decongestants                                   • Medications                              • Peripheral edema
                 • Renovascular disease                            • Drug overdose                            • Retinal examination
                 • Aortic coarctation                              • Headache, palpitation, blurred vision    
                 • Endocrine causes                                                                           

**Note:** Copyright © 2012, Springer.

Adapted with permission from Chandar J, Zilleruelo G. Hypertensive crisis in children. *Pediatr Nephrol.* 2012;27(5):741--751.[@b1-oaem-4-085]

###### 

Examples of physical examination findings suggestive of definable hypertension

  System                                                                                     Finding[\*](#tfn7-oaem-4-085){ref-type="table-fn"}                                           Possible etiology
  ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------
  Vital signs                                                                                Tachycardia                                                                                  Hyperthyroidism, pheochromocytoma, neuroblastoma, primary hypertension
  Decreased lower extremity pulses; drop in blood pressure from upper to lower extremities   Coarctation of the aorta                                                                     
  Eyes                                                                                       Retinal changes                                                                              Severe hypertension, more likely to be associated with secondary hypertension
  Ear, nose, and throat                                                                      Adenotonsillar hypertrophy                                                                   Suggests association with sleep-disordered breathing (sleep apnea), snoring
  Height/weight                                                                              Growth retardation                                                                           Chronic renal failure
  Obesity (high body mass index)                                                             Primary hypertension                                                                         
  Truncal obesity                                                                            Cushing's syndrome, insulin resistance syndrome                                              
  Head and neck                                                                              Moon-faced                                                                                   Cushing's syndrome
  Elfin-faced                                                                                William's syndrome                                                                           
  Webbed neck                                                                                Turner syndrome                                                                              
  Thyromegaly                                                                                Hyperthyroidism                                                                              
  Skin                                                                                       Pallor, flushing, diaphoresis                                                                Pheochromocytoma
  Acne, hirsutism, striae                                                                    Cushing's syndrome, anabolic steroid use                                                     
  Café-au-lait spots                                                                         Neurofibromatosis                                                                            
  Adenoma sebaceum                                                                           Tuberous sclerosis                                                                           
  Malar rash                                                                                 Systemic lupus erythematosus                                                                 
  Acanthosis nigricans                                                                       Type 2 diabetes                                                                              
  Chest                                                                                      Widely spaced nipples                                                                        Turner syndrome
  Heart murmur                                                                               Coarctation of the aorta                                                                     
  Friction rub                                                                               Systemic lupus erythematosus (pericarditis), collagen-vascular disease, end stage            
  Apical heave                                                                               Renal disease with uremia                                                                    
  Left ventricular hypertrophy/chronic hypertension                                                                                                                                       
  Abdomen                                                                                    Mass                                                                                         Wilms tumor, neuroblastoma, pheochromocytoma
  Epigastric/flank bruit                                                                     Renal artery stenosis                                                                        
  Palpable kidneys                                                                           Polycystic kidney disease, hydronephrosis, multicystic dysplastic kidney, mass (see above)   
  Genitalia                                                                                  Ambiguous/virilization                                                                       Adrenal hyperplasia
  Extremities                                                                                Joint swelling                                                                               Systemic lupus erythematosus, collagen vascular disease
  Muscle weakness                                                                            Hyperaldosteronism, Liddle's syndrome                                                        

**Note:**

Findings listed are examples of findings and do not represent all possible physical findings. Adapted from Flynn, JT, Evaluation and management of hypertension in childhood. *Progress in Pediatric Cardiology*. 2001:12(2); 177--188. Copyright 2001 with permission from Elsevier.[@b30-oaem-4-085]

###### 

Antihypertensive drugs for management of severe hypertension in children 1--17 years old

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Most Useful[†](#tfn9-oaem-4-085){ref-type="table-fn"}                                                                                                                                              
  -------------------------------------------------------------------- --------------------------- -------------------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------
  Esmolol                                                              β-blocker                   100--500 mcg/kg/min                                                        iv infusion            Very short-acting---constant infusion preferred. May cause profound bradycardia.\
                                                                                                                                                                                                     Produced modest reductions in BP in a pediatric clinical trial.

  Hydralazine                                                          Vasodilator                 0.2--0.6 mg/kg/dose                                                        iv, im                 Should be given every 4 hours when given iv bolus.\
                                                                                                                                                                                                     Recommended dose is lower than FDA label.

  Labetalol                                                            α- and β- blocker           bolus: 0.2--1.0 mg/kg/dose up to 40 mg/dose infusion: 0.25--3.0 mg/kg/hr   iv bolus or infusion   Asthma and overt heart failure are relative contra-indications.

  Nicardipine                                                          Calcium channel blocker     1--3 mcg/kg/min                                                            iv infusion            May cause reflex tachycardia.

  Sodium nitroprusside                                                 Vasodilator                 0.53--10 mcg/kg/min                                                        iv infusion            Monitor cyanide levels with prolonged (\>72 hr) use or in renal failure; or coadminister with sodium thiosulfate.

  **Occasionally useful[‡](#tfn10-oaem-4-085){ref-type="table-fn"}**                                                                                                                                 

  **Drug**                                                             **Class**                   **Dose[\*](#tfn11-oaem-4-085){ref-type="table-fn"}**                       **Route**              **Comments**

                                                                                                                                                                                                     

  Clonidine                                                            Central α-agonist           0.05--0.1 mg/dose may be repeated up to 0.8 mg total dose                  po                     Side effects include dry mouth and sedation.

  Enalaprilat                                                          ACE inhibitor               0.05--0.1 mg/kg/dose up to 1.25 mg/dose                                    iv bolus               May cause prolonged hypotension and acute renal failure, especially in neonates.

  Fenoldopam                                                           Dopamine receptor agonist   0.2--0.8 mcg/kg/min                                                        iv infusion            Produced modest reductions in BP in a pediatric clinical trial in patients up to 12 years.

  Isradipine                                                           Calcium channel blocker     0.05--0.1 mg/kg/dose                                                       po                     Stable suspension can be compounded.

  Minoxidil                                                            Vasodilator                 0.1--0.2 mg/kg/dose                                                        po                     Most potent oral vasodilator; long-acting.
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Hydralizine is US FDA approved for the treatment of hypertensive emergencies and hypertensive urgencies in the pediatric population. Sodium nitroprusside is US FDA approved for the treatment of hypertensive emergencies in the pediatric population. Fenoldopam and Minoxidil are US FDA approved for the treatment of hypertensive urgencies in the pediatric population. Pediatric hypertensive emergencies and/or hypertensive urgencies are not US FDA approved indications for the use of esmolol, labetalol, nicardipine, clonidine, enalaprilat, or isradipine. Reprinted from U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute. NIH Publication No. 05-5267. 2005.[@b4-oaem-4-085]

Useful for hypertensive emergencies and some hypertensive urgencies.

Useful for hypertensive urgencies and some hypertensive emergencies.

All dosing recommendations are based upon expert opinion or case series data except as otherwise noted.

**Abbreviations:** ACE, angiotensin-converting enzyme; im, intramuscular; iv, intravenous; po, oral.
